Syndax Pharmaceuticals Inc (SNDX) stock
SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.20+0.07 (+0.77%)
Close on Nov 17, 2026Market cap $821.53MP/E –Yield –
Syndax Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Syndax Pharmaceuticals's total assets was $692.67M at Sep 30, 2026. For fiscal 2025 it was $529.71M, down 26.9% from the year before. Over ten years it grew 19.4% a year on average. The highest annual figure on record is $724.82M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $529.71M | -26.9% |
| FY2024 | Dec 31, 2024 | $724.82M | +18.3% |
| FY2023 | Dec 31, 2023 | $612.88M | +23.3% |
| FY2022 | Dec 31, 2022 | $497.24M | +10.6% |
| FY2021 | Dec 31, 2021 | $449.66M | +49.6% |
| FY2020 | Dec 31, 2020 | $300.61M | +373.2% |
| FY2019 | Dec 31, 2019 | $63.53M | -24.3% |
| FY2018 | Dec 31, 2018 | $83.94M | -38.8% |
| FY2017 | Dec 31, 2017 | $137.19M | +25.8% |
| FY2016 | Dec 31, 2016 | $109.01M | +21.3% |
| FY2015 | Dec 31, 2015 | $89.90M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $692.67M | +25.5% |
| Q2 FY2026 | Jun 30, 2026 | $703.65M | +18.0% |
| Q1 FY2026 | Mar 31, 2026 | $472.67M | -26.2% |
| Q4 FY2025 | Dec 31, 2025 | $529.71M | -26.9% |
| Q3 FY2025 | Sep 30, 2025 | $551.79M | +29.6% |
| Q2 FY2025 | Jun 30, 2025 | $596.15M | +25.0% |
| Q1 FY2025 | Mar 31, 2025 | $640.71M | +18.0% |
| Q4 FY2024 | Dec 31, 2024 | $724.82M | +18.3% |
| Q3 FY2024 | Sep 30, 2024 | $425.81M | +6.7% |
| Q2 FY2024 | Jun 30, 2024 | $476.95M | +10.6% |
| Q1 FY2024 | Mar 31, 2024 | $543.03M | +18.1% |
| Q4 FY2023 | Dec 31, 2023 | $612.88M | +23.3% |
| Q3 FY2023 | Sep 30, 2023 | $399.22M | +11.0% |
| Q2 FY2023 | Jun 30, 2023 | $431.34M | +6.1% |
| Q1 FY2023 | Mar 31, 2023 | $459.83M | +8.9% |
| Q4 FY2022 | Dec 31, 2022 | $497.24M | +10.6% |
| Q3 FY2022 | Sep 30, 2022 | $359.69M | +50.2% |
| Q2 FY2022 | Jun 30, 2022 | $406.44M | +54.5% |
| Q1 FY2022 | Mar 31, 2022 | $422.22M | +51.0% |
| Q4 FY2021 | Dec 31, 2021 | $449.66M | +49.6% |
| Q3 FY2021 | Sep 30, 2021 | $239.50M | +33.6% |
| Q2 FY2021 | Jun 30, 2021 | $263.06M | +36.6% |
| Q1 FY2021 | Mar 31, 2021 | $279.67M | +166.0% |
| Q4 FY2020 | Dec 31, 2020 | $300.61M | +373.2% |
| Q3 FY2020 | Sep 30, 2020 | $179.31M | +134.8% |
| Q2 FY2020 | Jun 30, 2020 | $192.63M | +120.4% |
| Q1 FY2020 | Mar 31, 2020 | $105.16M | +5.8% |
| Q4 FY2019 | Dec 31, 2019 | $63.53M | -24.3% |
| Q3 FY2019 | Sep 30, 2019 | $76.38M | -20.8% |
| Q2 FY2019 | Jun 30, 2019 | $87.39M | -17.1% |
| Q1 FY2019 | Mar 31, 2019 | $99.39M | -17.1% |
| Q4 FY2018 | Dec 31, 2018 | $83.94M | -38.8% |
| Q3 FY2018 | Sep 30, 2018 | $96.47M | -22.5% |
| Q2 FY2018 | Jun 30, 2018 | $105.37M | -21.8% |
| Q1 FY2018 | Mar 31, 2018 | $119.96M | +22.8% |
| Q4 FY2017 | Dec 31, 2017 | $137.19M | +25.8% |
| Q3 FY2017 | Sep 30, 2017 | $124.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $134.67M | – |
| Q1 FY2017 | Mar 31, 2017 | $97.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $109.01M | – |
See a number that looks wrong?